Merck and Moderna Report Promising Results for Melanoma Vaccine Trial
A novel mRNA-based vaccine developed by pharmaceutical partners Merck and Moderna has shown a 42 percent reduction in mortality and recurrence rates for patients with late-stage melanoma.




























